



## **CardioFocus to Participate at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference**

**MARLBOROUGH, Mass., August 12, 2021** – [CardioFocus, Inc.](http://www.CardioFocus.com), a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that its management team will attend investor meetings at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference from August 16-17, 2021.

### **About the HeartLight X3 System**

The HeartLight X3 System is a revolutionary catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for atrial fibrillation (AFib). Using direct tissue visualization, titratable laser energy and compliant balloon technology, the HeartLight X3 System is a truly differentiated PVI solution. HeartLight is a treatment option for some patients whose AFib is insufficiently controlled with medication<sup>1</sup>. More than 33 million patients worldwide suffer from AFib<sup>2</sup>, which has been associated with significant symptoms, functional impairment, stroke, cognitive decline, heart failure, and reduced longevity. HeartLight X3 offers a unique RAPID mode, which leverages a precise motor control system that enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician. Clinical studies of the HeartLight X3 System demonstrated that AFib patients can be treated quickly resulting in consistently reduced procedure times with excellent procedure time predictability.<sup>3,4</sup>

### **About CardioFocus, Inc.**

Headquartered in Marlborough, MA, CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AFib), the most common heart arrhythmia. The HeartLight X3 catheter, endoscope, sheath, console and balloon fill media are all manufactured in the USA. For more information, visit <http://www.CardioFocus.com>.

### Media Relations

Sean Leous

Westwicke/ICR

646-866-4012

[Sean.Leous@westwicke.com](mailto:Sean.Leous@westwicke.com)

<sup>1</sup> In the United States, the HeartLight System is indicated to treat drug refractory, symptomatic, paroxysmal atrial fibrillation (AFib).

<sup>2</sup> Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. *Circulation*. 2014 Feb 25;129(8):837-47.

<sup>3</sup> X3 total procedure time was statistically significantly shorter than the original HeartLight and irrigated radiofrequency ablation (RF) ablation based on a comparison to the original HeartLight pivotal study (historical control).

<sup>4</sup> Predictability is determined by the standard deviation of the procedure time.